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ABSTRACT
Recent research has focusedon thehypothesis that the growth and regenerationof glioblastoma (GB)
is sustained by a subpopulation of self-renewing stem-like cells. This has led to the prediction that
molecularmarkers for cancer stem cells in GBmay provide a treatment target. One candidatemarker
is CD15:wewanted to determine if CD15 represented a credible stemcellmarker inGB.We first dem-
onstrated that CD15-positive (CD15+) cells were less proliferative than their CD15-negative (CD152)
counterparts in 10 patient GB tumors. Next we compared the proliferative activity of CD15+ and
CD152 cells in vitro using tumor-initiating primary GB cell lines (TICs) and found no difference in pro-
liferative behavior. Furthermore, TICs sorted for CD15+ and CD152 were not significantly different
cytogenetically or in terms of gene expression profile. Sorted single CD15+ and CD152 cells were
equally capableof reconstitutingaheterogeneouspopulation containingbothCD15+andCD152 cells
over time, and both CD15+ and CD152 cells were able to generate tumors in vivo. No difference was
found in thephenotypicorgenomicbehaviorofCD15+cells comparedwithCD152 cells fromthesame
patient. Moreover, we found that in vitro, cells were able to interconvert between the CD15+ and
CD152 states. Our data challenge the utility of CD15 as a cancer stem cell marker. STEM CELLS
TRANSLATIONAL MEDICINE 2015;4:822–831
SIGNIFICANCE
The data from this study contribute to the ongoing debate about the role of cancer stem cells in glio-
magenesis. Results showed that CD15, amarker previously thought to be a cancer stem-likemarker in
glioblastoma, couldnot isolate aphenotypically or genetically distinct population.Moreover, isolated
CD15-positiveand -negativecellswereable togeneratemixedpopulationsofglioblastomacells invitro.
INTRODUCTION
Glioblastoma (GB), the most common and ag-
gressive neuroepithelial malignancy, is character-
ized by genetic instability and complex clonal
evolutionary dynamics that result in histopatho-
logical diversity and clinical heterogeneity [1].
The evolution of disease complexity in cancer is
generated through genetic and epigenetic mecha-
nisms that form the basis of the clonal evolution
model of oncogenesis [2]. More recently, the can-
cer stem cell hypothesis has challenged stochastic
evolutionbypositing that cancers arehierarchically
organized [3]. In this model, oncogenesis is driven
by a subpopulation of cancer stem cells with prog-
eny that undergo irreversible epigenetic changes,
analogous to normal cell differentiation, resulting
in nontumorigenic populations that contribute
the bulk of the tumor. The hypothesis is attractive
because elimination of the aggressive subpopula-
tion could result in disease cure.
Although cancer stem cells (CSCs) and tumor-
initiating cells (TICs) have been relatively estab-
lished in some cancers, including leukemia [4, 5],
germ cell tumors [6, 7], breast [8], and colon can-
cers [9, 10], their existence seemsunlikely in other
cancers including lymphoma and melanoma
[11–13].
In neuroepithelial malignancies, the exis-
tence of CSCs and TICs remains controversial
because no robust cell-surface marker has been
identified to distinguish prospectively tumori-
genic and nontumorigenic cell populations [14–19].
Initial data identifyingCD133/prominin1asamarker
that enriched for TICs in GB [20–22] were subse-
quently challenged [23–26]. More recently, the cell
surface marker CD15/stage-specific embryonic anti-
gen 1 has been identified as a possible TICmarker in
GB andmedulloblastoma [23, 27–30]. CD15 is a car-
bohydrate moiety expressed by a variety of cells in-
cluding neural stem and progenitor cells and is
developmentally regulated in the brain, where it is
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thought to play a role in cell-cell interaction during neuronal
development [31–35].
Based on these data, we wanted to determine whether CD15-
expressing cells inGB represented a TICmarker and apotential ther-
apeutic target in clinically symptomatic patients with GB. We used
a combined approach to characterize CD15-expressing cells in pa-
tient tumors, in vitro, and in xenograft animal models.
MATERIALS AND METHODS
Cell Line Derivation
Tissue collectionprotocolswere compliantwith theU.K.Human
Tissue Act 2004 (HTA License ref 12315) and approved by the
local regional ethics committee (LREC ref 04/Q0108/60). In-
formed consent was obtained from each patient through our
research clinic [36]. Cell derivation and the tumor formation
assay have been described previously [19]. Briefly, anonymized
tissue was mechanically minced, and cells were seeded in de-
fined serum-free (SF) medium and allowed to form primary
aggregates. These spheroid aggregates were collected and
plated, without dissociation, onto flasks coated with extracel-
lular matrix (ECM; 1:10 dilution; Sigma-Aldrich, St. Louis, MO,
https://www.sigmaaldrich.com) and allowed to formaprimary
monolayer. As the primarymonolayer approached confluence,
cells were passaged to generate the subsequent monolayers.
Cells were cultured in 10 ml SF medium (phenol red-free Neu-
robasal A, Invitrogen; Thermo Fisher Scientific, Waltham, MA,
http://www.thermofisher.com) with 2 mM L-glutamine and
1% volume/volume (vol/vol) penicillin/streptomycin/Fungizone
solution with 20 ng/ml human epidermal growth factor (Sigma-
Aldrich), 20 ng/ml basic fibroblast growth factor (R&D Systems,
Minneapolis, MN, http://www.rndsystems.com), 20 ng/ml hepa-
rin (Sigma-Aldrich), 2% vol/vol B27 SF supplement (Invitrogen;
Thermo Fisher Scientific), and 1% N2 SF supplement (Invitrogen;
Thermo Fisher Scientific).
For the clonal analysis experiments, single CD15-positive
(CD15+) and CD15-negative (CD152) cells were seeded into 96-
well plates and allowed to grow for 8 weeks, at which point the
number of colonies was quantified. All experiments were con-
ducted in triplicate.
For the 12-day clonal analysis time course, single cells were
seeded into 96-well plates, but prior to seeding, 96-well plates
were coated in 1:10 ECM. This allowed cells to proliferate as
a monolayer.
Staining and Imaging
Table 1 summarizes the primary and secondary antibodies
used for immunohistochemistry and immunocytochemistry
in this study.
The immunocytochemistry protocol was conducted at room
temperaturewith threephosphate-buffered saline (PBS; pH7.4)
washes between each incubation; samples were gently shaken
during incubation. Cells were fixed for 10 minutes with 4%
paraformaldehyde (PFA; Sigma-Aldrich) and then washed with
PBS and permeabilized with 1% Triton X for 5 minutes (if indi-
cated in Table 1) and incubatedwith blocking buffer (5%bovine
serum albumin [BSA; Sigma-Aldrich] in PBS) for 45 minutes.
Block was removed, and cells were then incubated with pri-
mary antibodies with 1% BSA for 2 hours. Appropriate sec-
ondary antibodies (Alexa Fluor conjugates from Invitrogen
Molecular Probes; Thermo Fisher Scientific) were used at a dilu-
tion of 1:500 in PBS for 1 hour. Cells were then incubated with
a 1:10,000 dilution of Hoechst 33342 (Enzo Life Sciences, Farm-
ingdale, NY, http://www.enzolifesciences.com) for 5 minutes
before a final washing step. Samples were stored at 4°C wrap-
ped with parafilm. Before image acquisition, PBS was removed
and glass coverslips were placed on cells. When using the com-
bination ofNG2 andCD15 antibodies, the antibodieswere used
separately.With primary and secondary antibodies for NG2 ap-
plied first, as described in this paragraph, before a further fixing
stage in 4% PFA for 5 minutes, the protocol described above
was repeated for CD15.
For the immunohistochemistry protocol, patient tumor sec-
tions that had not been fixed were defrosted in 4% PFA for
2 minutes. Patient tumor sections were washed before adding
50ml/cm2 of blocking solution with 0.25% Triton X for 30minutes.
Blocking solution was removed and replaced with the primary an-
tibodyat theconcentration indicated inTable1.Thiswas incubated
for 12–16hours at room temperature before being gentlywashed.
Appropriate secondary antibodies from Invitrogen (Thermo Fisher
Scientific) were used at a concentration of 1:500, the glial fibrillary
acidic protein (GFAP) antibody was used at this stage. Finally
Hoechst 33342 was added at a concentration of 1:10,000 for
5 minutes. Sections were washed before being mounted with
Vectashield mounting medium (Vector Laboratories, Burlingame,
CA, https://www.vectorlabs.com).
For hematoxylin and eosin (H&E) staining, sections of 10 mm
were defrosted and fixed in 4% PFA for 3 minutes. Automated
staining was performed by Leica Autostainer XL (Leica Microsys-
tems, Buffalo Grove, IL, http://www.leicabiosystems.com). Slides
were then coverslipped on the automated Leica CV 500.
Immunofluorescence stainings were imaged on a Zeiss
Axioplan 2 confocal microscope with Zeiss software or a Zeiss
fluorescent light microscope using Axio vision software as indi-
cated (Carl Zeiss, Jena, Germany, http://www.zeiss.com). H&E
staining was imaged using an Olympus BX41 light microscope
(Olympus, Tokyo, Japan, http://www.olympusamerica.com).
Fluorescence-Activated Cell Sorting
Cells were incubated with 20 ml/million cells of FITC-conjugated
CD15 antibody (mouse monoclonal antibody clone; BD Biosci-
ence, San Jose, CA, https://www.bdbiosciences.com) [23] for
15 minutes in the dark on ice, with frequent gentle shaking.
The cells were then washed twice in Hanks’ balanced saline solu-
tion (HBSS). After the final wash, 2 ml of mediumwas added, and
the suspension of cells was immediately taken for fluorescence-
activated cell sorting (FACS) on ice, with light excluded.
Flow-cytometricanalysisandsortingwerecarriedoutonaMoFlo
high-speed sorter (Beckman Coulter, Pasadena, CA, https://www.
beckmancoulter.com). The MoFlo cell sorter was calibrated using
fluorospheres (SPHERO Rainbow Fluorescent Particles; Spherotech
Inc., Lake Forest, IL, http://www.spherotech.com) to align laser-
shaping optics on a daily basis.
Single-line visible light (488 nm) from an argon laser (Coher-
ent, Santa Clara, CA, http://www.coherent.com) was focused
onto the stream with spherical beam-shaping optics. Fluores-
cence was measured with a 530/30 band-pass filter for analysis
of FITC-conjugated CD15 antibody fluorescence in front of an
H957 photomultiplier tube. The forward scatter signal was used
to trigger acquisition. Signals for forward and side scatter were
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obtained in linear mode, and the fluorescence signal was obtained
in logarithmicmode. “Single” sort modewas used to sort cells into
96-wells plates, and “purify” sort mode was used to sort cells into
tubes. Sheath pressure was ∼33–34C, and a 100-mm nozzle was
used. Drop drive frequency and amplitude were calibrated each
day to ensure optimal drop formation and drop delay.
Analysis was performed using Summit software (versions 4.2
and 4.3.1; Beckman Coulter).
Sorting was performed at room temperature. Control cells
were analyzed initially, and gating was set for this population be-
fore labeled cells were analyzed and sorted. Most dead cells and
debris were excluded on the basis of forward and side scatter.
Elimination of doublets andmultipletswas performedusingpulse
width as a selection criterion to ensure that only single cells were
sorted. Finally, the fluorescence gatingwas adjusted for the auto-
and background fluorescence signal produced by unlabeled con-
trol populations. Only cells with greater fluorescence than the
control population were selected. These cells were deemed to
be positive for CD15. The cells with approximately half a log scale
over basal values of CD15 where selected for experiments.
Cells were sorted as a bulk population into 1.5-ml Eppendorf
tubes or sorted as single cells per well into 96-well plates. Single
sortmodewasused tosort cells into96-wells plates, andpurify sort
mode to sort into tubes. Trigger ratewas up to∼1,000–4,000 cells
per second and ∼300–900 cells per second for purify and single
sortmodes, respectively. Between50,000 and 300,000 sorted cells
were collected from each sample into tubes. For clonal experi-
ments, positive and negative cells were sorted onto plates sepa-
rately using relevant gating strategy based on FITC-conjugated
CD15 fluorescence.
DNA and RNA Purification, Single-Nucleotide
Polymorphism Array, and Microarray
DNAandRNAwereextractedusing theAllprepDNA/RNAkit (Qiagen,
Venlo, The Netherlands, https://www.qiagen.com), according to the
manufacturer’s instructions. Final concentration and purity were
assessed using the NanoDrop system (Thermo Fisher Scientific).
Illuminasingle-nucleotidepolymorphism(SNP;HumanCytoSNP-
12; Illumina, San Diego, CA, http://www.illumina.com) and
gene expression arrays (WG6) were used to interrogate cytoge-
netic and expression differences between CD15+ and CD152
lines. Array hybridization and data analysis was performed by
Cambridge Genomic Services (Cambridge, U.K., http://www.cgs.
path.cam.ac.uk). A paired sample comparison was used to run
statistical analysis, as reported previously [37]. Array quality
control was assessed with Illumina’s GenomeStudio software.
R software (lumi Bioconductor package; R Foundation, Vienna,
Austria, http://www.r-project.org) was used for processing and
to assess differential expression (lumi limma package). Unsuper-
vised hierarchical clustering of gene expression patterns and
principal component analysis was performed with the multiex-
periment viewer [38].
Animal Transplantation
All animals were housed and maintained in accordance with the
U.K. Animal (Scientific Procedures) Act 1986 and the Cambridge
University Commission for Animal Health. Tissue was implanted
as single-cell suspensions into subcutaneous tissue of male nude
miceaged6–8weeks. A suspensionof33105 FACS-sortedCD15+
and CD152 GB cells were prepared in 50ml of HBSS and injected
after beingmixedwith100–200ml of ECM into thedermal layer of
the hind limbs. CD15+ cells were implanted in the left flank, and
CD152 cells were implanted in the right flank from the same cell
line at the same time. Animals were sacrificed at 6 months.
Statistical Analysis
Statistical analysis was conducted using Microsoft Excel
(Microsoft, Redmond, WA, http://www.microsoft.com) and
Social Science Statistics (http://www.socscistatistics.com/tests/
mannwhitney/Default.aspx).
RESULTS
We began by examining the proliferation status of CD15 cells
in representative, histologically confirmed clinical samples
obtained from10patientswithGB (typical H&E) (Fig. 1A). Immu-
nohistochemistry for CD15, the astrocytic marker GFAP and
the proliferation-associated antigen Ki-67, was performed on
cryosections. Because CD15also labels leukocytes,we costained
tumor sections with GFAP, which is expressed in GB and astro-
cytoma cells but not neutrophils [39–42]. An average of 8,000
nucleated GFAP-positive cells were scored in each tumor. Ex-
pression of CD15 in our clinical samples was rare: CD15+ cells
represented 0.03%–0.24% of GFAP-positive cells. There was
a significant difference between the number of cycling cells in
the CD15+ and CD152 populations (p , .05). Only 0.003% of
Table 1. Primary antibodies
Target Clone Supplier and order number Host species Isotype Dilution Notes
NG2 Polyclonal Millipore, Ab5320 Rabbit 1:250
Nestin Polyclonal Millipore, Ab5922 Rabbit IgG 1:250 Permeabilized
PDGFRA Gift, Dr. William Stallcupa Rabbit 1:50
Olig2 Polyclonal Abcam, Ab42453 Rabbit 1:250 Permeabilized
Sox2 Polyclonal Abcam, Ab15830 Rabbit 1:100 Permeabilized
CD15 MMA BD Bioscience, 347420 Mouse IgM 1:10 (sections);
1:20 (cells)
Ki-67 Mib1 Dako, M7240 Mouse IgG1 k 1:100 Permeabilized
Ki-67 Sp6 Abcam, 16667 Rabbit IgG 1:100 Permeabilized
GFAP Abcam, 21294 Mouse IgG 1:100 488 conjugated
Millipore, Billerica, MA, http://www.emdmillipore.com; Abcam, Cambridge, MA, http://www.abcam.com; Dako, Carpinteria, CA, http://www.dako.com.
aStanford Burnham Medical Research Institute.
Abbreviations: GFAP, glial fibrillary acidic protein; MMA, mouse monoclonal antibody.
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CD15+GFAP+ cells coexpressed Ki-67, amarker of cycling glioma
cells [43, 44] (Fig. 1B, 1C), in contrast to 5.49% of cells that were
CD152, GFAPpositive, and Ki-67 positive. The scarcity and relative
proliferative quiescence of the CD15+ population within GB sug-
gests that it is cycling CD152 cells that drive tumor growth.
We next set out to examine the fate of cells from early pas-
sage (passage ,10) cultures from 10 tumors representative
of the patient samples analyzed above. The optimal method
of culturing GB TICs has provoked controversy between those
who culture cells in suspension as spheres and those who favor
adherent cultures [45–47]. For these experiments, we used
a hybrid protocol in which cells are initially cultured as spheres
and then grown as a monolayer [19]. This protocol is optimal
for these experiments because the fate of individual cells
can be followed in adherent cultures. We validated each cell
line as TICs by confirming tumorigenicity in vivo [19, 48]. We
also showed, using an SNP array, that the primary cells were
cytogenetically similar to both the parent tumor and the exper-
imental xenograft derived from the corresponding cell line in
two of our TICs (supplemental online Table 1).
Both CD15+ and CD152 cells were present in all TIC lines in-
vestigated. A paired sample comparison of the cytogenetic pro-
file of FACS CD15+ and CD152 cells from two of the TIC lines,
using whole-genome SNP arrays, confirmed that CD15+ and
CD152 populations had no statistically significant cytogenetic
differences (Fig. 2A; supplemental online Tables 2, 3), indicating
a common clonal heritage. We compared whole-genome ex-
pression levels between CD15+ and CD152 cells from one TIC
line and failed to reject the null hypothesis (p . .01 after mul-
tiple testing correction), thus no differentially expressed genes
could be identified between positive and negative cells (Fig. 2B;
supplemental online Fig. 1).
To further examine differences between CD15+ and CD152
populations, we investigated the expression of five markers as-
sociated with neural stem or progenitor cells to see if these
markers could distinguish between CD15+ and CD152 cells in
three TIC lines in vitro. We cultured unsorted cells and used im-
munocytochemistry of a panel of markers and quantified the
number of CD15+ and CD152 cells that coexpressed each
marker; sample images from the cell line S1 are displayed in
Figure 3A. There were high levels of expression of the neural
stem cell markers nestin [49] and Sox2 [50] that did not differ
between CD15+ and CD152 cells (Fig. 3B). We next looked at
three markers of more committed neural progenitors. The tran-
scription factor Olig2 and the cell surface proteoglycan NG2 are
widely expressed in both glial progenitors and glial cancers [18,
51, 52] and PDGFRA, one of the earliest markers expressed by
cells committed to the oligodendrocyte lineage [53]. We found
these markers were similarly expressed in both CD15+ and
CD152 cells (Fig. 3B). We were unable to find a significant dif-
ference between CD15+ and CD152 cells on the basis of expres-
sion of any of the five markers associated with neural stem or
progenitor cells that we investigated. We also evaluated the ex-
pression of CD133, a putative cancer stem cell marker, but we
found lack of coexpressionwith CD15 and low level of CD133 ex-
pression (supplemental online Fig. 2). Given the controversy
about the reliability of CD133, we did not pursue any further
experiments using it as a marker.
We next evaluated whether CD15+ and CD152 populations
could reconstitute one another. Paired CD15+ and CD152 cell
Figure 1. CD15-positive (CD15+) glial fibrillary acidic protein-positive (GFAP+) cells from patient glioblastoma (GB) tumors are quiescent. (A):
Representative hematoxylin andeosin stainingof S1patient tumor. Scalebar =100mm. (B):Ki-67expression inCD15+andCD15-negative cells in
10 representative GB patient tumors. (C): Single slice confocal images of patient tumor S1. Immunohistochemical detection of Hoechst 3342
(blue), GFAP (green), CD15 (red), and Ki-67 (mauve). Scale bar = 10 mm.
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populations from the same TIC line were isolated and cultured
to determine whether CD15+ cells could be generated from
a marker-negative population and vice versa. Using FACS, paired
populations of CD15+/2 cells were isolated from three TIC lines.
We evaluated temporal changes in CD15 expression. At 10 and
20daysafter sorting,weobservedthat thesortedCD152population
began to express CD15 (Fig. 4A). This pattern of CD15 distribution
developed slowly, and the CD15+ fraction remained low (Fig. 4A).
In contrast,weobserved rapid emergenceof CD152 cells in isolated
CD15+ populations (Fig. 4A). By 30 days after sorting, both sorted
Figure 2. CD15-positive (CD15+) and CD15-negative (CD152) cells do not have significantly different cytogenetic or gene expression profiles.
Both CD15+ and CD152 cells from the S1 cell line have indistinguishable cytogenetic profile. Single-nucleotide polymorphism array results
shown by B allele frequency and log R ratio for two example chromosomes. Chromosome 1 (A) and 13 (B). (C): Hierarchical clustering of genes
from CD15+ and CD152 cells from the S1 cell line, demonstrated with gene expression array.
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cell populations had achieved an identical heterogeneous distribu-
tion of both CD15+ and CD152 cells (Fig. 4A) in all TICs investigated.
We concluded that cells interconvert between CD15+ and CD152
states.
To determinewhether the phenotypic behavior of CD15+/2
cells was a function of interaction with the cellular microenvi-
ronment, we isolated single CD15+ or CD152 cells from the
same TIC population of 10 different lines. We then evaluated
their ability to form new colonies and to interconvert between
the CD15+ and CD152 states. Single CD15+ and CD152 cells
were sorted and grown in 96-well plates for at least 6 weeks be-
fore being analyzed for CD15 expression (Fig. 4B). Analysis by
flow cytometry demonstrated that both single CD15+ and
CD152 cells were able to form CD15+ progeny (Fig. 4B). These
data from population studies and single-cell studies indicate
that CD15+ andCD152 cells in GBdonot display a unidirectional
cellular hierarchy.
In parallel, we evaluated the ability of single CD15+ or CD152
cells to form new colonies in 96-well plates from each of our 10 cell
lines. Therewasnosignificantdifference incolony-formingability, as
demonstrated by the formation of spheres, for single CD15+ and
CD152 cells in any of the TIC lines (p. .5) (Fig. 4C). This demon-
strates that CD15+ cells do not have a colony-forming advantage
in vitro when compared with CD152 cells.
We were next interested in a more detailed investigation of
single CD15+ and CD152 clones at early time points. We isolated
single CD15+ or CD152 cells from the same TIC population and
tracked cell proliferation of cells, grown as a monolayer, over
a 12-day time course for each specific clone. We studied 192
clones per cell line. We found no significant difference between
clone sizes in CD15+ and CD152 cells on days 2, 4, 7, and 12 after
sorting in either of the two cell lines investigated (Fig. 4D;
supplemental online Fig. 3).
Our observations of clinical samples coupled with the identi-
cal pattern of phenotypic behavior of CD15+/2 cells under de-
fined experimental conditions in vitro led us to hypothesize
that CD15 expression would not distinguish distinct GB cell pop-
ulations in vivo. To test this hypothesis, we implanted 300,000
CD15+ and CD152 cells subcutaneously into the flanks of nude
mice to observe any tumor formation. We used two TIC lines cul-
tured from two unique patient GB samples and tested each cell
line in triplicate. Animals were culled after 40 weeks or when
tumors reached 15 mm, whichever came first. By 40 weeks, 5
of 6 paired implants had generated tumors. In each case, both
CD15+ and CD152 cells generated tumors. We did not observe
any cases in which CD15+ GB cells generated a tumor but the
paired CD152 cells did not (Fig. 5).
DISCUSSION
The application of the cancer stem cell hierarchical model to GB
remains controversial. No cell surfacemarker has been found that
will reliably discriminate a tumor-initiating cell population from
an epigenetically stable nontumorigenic population. Studies on
cell populations defined by the expression of CD133 and CD44
have not reliably isolated tumor-initiating cells [28, 54–58].
We were unable to replicate previous data suggesting that
CD15+ cells were more clonogenic or tumor forming or had
higher expression of stem cell-associated markers Sox2 and
Olig2 than their CD152 counterparts [23].We found that paired
CD15+/2 cells were equally tumorigenic and clonogenic. Possi-
ble explanations for these differences in results include the
effects of different experimental systems and conditions on
colony-forming and tumor-forming assays [12]. We used differ-
ent mouse model systems and different locations for xenograft
compared with previous studies [23]. These previous studies
Figure 3. CD15+ and CD152 cells from glioblastoma cell lines have similar expression of neural stem cell markers and neural progenitor cell
markers. (A): Single-slice confocal images of stem cell markers and neural progenitor cell markers in the cell line S1. (B): The proportion of cells
expressing neural stem cell and neural progenitor cell markers in three cell lines.
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used orthotopic xenogeneic implantation into neonatal SCID
mice; in comparison,weusedheterotopic xenogenic subcutane-
ous implantation into nude mice. We chose this model because
it allowed us to visualize tumor formation directly, even for
small tumors that the resolution of small animal imaging would
struggle to detect in orthotopic models. Although heterotopic
implants are not exposed to organ-specific tumor-stroma inter-
actions, it is recognized that analysis of any tumor-host interac-
tions using a xenogeneic model of any kind must be interpreted
with caution. For these reasons, we have confined our in vivo
analysis to comparisons of paired CD15+ and CD152 cell popu-
lations exposed to the same environmental conditions in vivo to
Figure4. CD15-positive (CD15+) andCD15-negative (CD152) populations fromglioblastoma (GB) sortedby fluorescence-activated cell sorting
(FACs) established a phenotypic equilibrium that recapitulated the original GB cell line phenotype. (A): The proportion of CD15+ cells in a pop-
ulation of GB cells over time, the initial populations were sorted by FACS as CD15+ and CD152. (B): Single CD15+ and CD152 cells were sorted
into96-well plates and allowed toproliferate for at least 6weeks, afterwhichCD15expressionwas analyzedby FACS. The table shows the results
of this experiment in 10 tumor-initiating cell lines. (C): Colony-forming ability of single CD15+ and CD152 cells from 10 GB cell lines after an
8-week timecourse. (D):Average clone sizewitherror bars showing standarddeviationof thedata set. The varietyof clone sizeswaswideat each
time point. The table shows the results of Mann-Whitney values at each time point. Abbreviations: FACS, fluorescence-activated cell sorting;
GB, glioblastoma; W, week.
Figure 5. CD15-positive (CD15+) and CD15-negative (CD152) populations from glioblastoma sorted by fluorescence-activated cell sorting
(FACS) are equally tumorigenic in nudemice. Tumor-initiating cell lines were sorted by FACs for CD15+ and CD152 cells, which were implanted
into nude mice. Examples of tumors with corresponding histology and the results of tumor forming assays.
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show that in each pair both CD15+ and CD152 cells were simi-
larly tumorigenic. These data support our findings in patient tu-
mor samples, in whichwe found that CD15+ cells were notmore
regularly cycling than their CD152 counterparts. It also supports
our in vitro findings that CD15+ clones did not have a survival
advantage or early proliferative advantage compared with
matched CD152 clones.
The number of CD15 cells in our tissue analyses was low com-
paredwith previous reports [23], raising the possibility that these
studies included additional cell subpopulations in their CD15+
samples. CD15 is widely expressed on macrophages and neutro-
phils, onwhich itmediates phagocytosis and chemotaxis [59], and
in cancers including lymphoma, leukemia, gastric cancer, and he-
patocellular carcinoma [60, 61]. High-grade glioma displays a het-
erogeneous parenchymal cell population including peripheral
immune cells and microglia [62]. Consequently, we excluded leu-
kocytic cell populations by costaining for GFAP, which is not
expressed by leukocytes, to restrict CD15 expression to GB cells
in this study, possibly explaining why CD15 cell counts appear
lower in our tissue samples.
Although CSCs and TICs have been well established in some
cancers including leukemia [4,5],germcell tumors[6,7],andbreast
[8] and colon carcinomas [9, 10], their existence seems unlikely in
other cancers including melanoma [11, 12] and lymphoma [13].
Data identifying the glycoprotein CD133 as a putative CSC marker
in glioblastoma [20–22] have subsequently been challenged
[23–26], and the case for a cellular hierarchical organization in
GBM remains unproven. Our data challenge the use of CD15 as
a marker of a hierarchy in GB. We found that single cells, both
CD15+ and CD152, were able to generate mixed CD15+ and
CD152 populations in vitro.
Increasingly molecular genetic data indicate that in cancer
disease, complexity develops as a result of a branched pattern of
evolution [63–66], resulting in previously unrecognized levels of
intratumor heterogeneity in which genetically diverse cancer cell
clones coexistwithassociatedvariegatedphenotypes.Neuroepithe-
lial malignancies including medulloblastoma and GB demonstrate
similarevolutionarycomplexity [65–69].Theclonaldiversityandrap-
idly branching evolution of GB [70] represent a challenging environ-
ment in which to identify an epigenetically stable common clonal
ancestor consistent with the cancer stem cell hypothesis [71].
We were not able to find a difference in the phenotypic or ge-
nomic characteristics of CD15+ cells compared with the CD152
population. Sorted CD15+ and CD152 cells were capable of recon-
stituting a heterogeneous population containing both CD15+ and
CD152 cells over time, suggesting that, in vitro, cells were able
to interconvert between CD15+ and CD152 states. Our observa-
tions that sorted CD15+/2 cells gave rise to positive and negative
cells in a nonhierarchical manner suggest that the term “cancer
stem cell” might represent a dynamic state. Consistent with this
concept, clonal heterogeneity does not necessarily depend on cel-
lular hierarchybecausegenetically identical cells canexhibit pheno-
typic diversity due to stochastic variability in gene expression and
associated signaling pathways [72]. Consequently, expression of
CD15maybetransient, reflectingan intrinsic functional stateduring
progression through the cell cycle or a response to microenviron-
mental selection pressures. This may explain the vanishingly small
number of cycling CD15 cells we observed in clinical specimens
compared with the relative ease with which CD15-expressing cell
lines could be generated in vitro.
CONCLUSION
We conclude that CD15 does not represent a robust cell-surface
marker able to prospectively distinguish a rapidly proliferating,
tumorigenic, or stem-like population in GB. We suggest that
the several markers, including CD15, that have been reported
to identify a cancer stem cell in GB simply reflect clonal and func-
tional heterogeneity within each GB. Indeed, stochastic and hier-
archical models have been previously considered alternative
mechanismsof cancerprogression [73].Analternativehypothesis
is that they arepart of the sameprocess because clonal diversity is
likely to be generated and sustained by genetically distinct CSCs,
which provide the units for evolutionary selection [74, 75]. Evi-
dence in support of this hypothesis exists in leukemia [63, 76]
and it has been suggested that GBs similarly harbor genetically di-
verse tumor cell populations [77]. Such insights are important for
understanding treatment failure because it is the resistant dis-
ease emerging from a clonally heterogeneous population that ul-
timately kills patients.
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